[go: up one dir, main page]

WO2021154188A1 - Composition pharmaceutique appropriée pour une administration vaginale - Google Patents

Composition pharmaceutique appropriée pour une administration vaginale Download PDF

Info

Publication number
WO2021154188A1
WO2021154188A1 PCT/TR2021/050086 TR2021050086W WO2021154188A1 WO 2021154188 A1 WO2021154188 A1 WO 2021154188A1 TR 2021050086 W TR2021050086 W TR 2021050086W WO 2021154188 A1 WO2021154188 A1 WO 2021154188A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
fenticonazole
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2021/050086
Other languages
English (en)
Inventor
Gulay YELKEN DEMIREL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exeltis Ilac Sanayii Ve Ticaret AS
Original Assignee
Exeltis Ilac Sanayii Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exeltis Ilac Sanayii Ve Ticaret AS filed Critical Exeltis Ilac Sanayii Ve Ticaret AS
Priority to BR112022015112A priority Critical patent/BR112022015112A2/pt
Priority to MX2022009303A priority patent/MX2022009303A/es
Priority to EP21748063.1A priority patent/EP4096655A4/fr
Publication of WO2021154188A1 publication Critical patent/WO2021154188A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention is related to a pharmaceutical composition suitable for vaginal delivery, as well as to the pharmaceutical composition for use in the treatment of infectious diseases in the female reproductive system. More particularly, the invention relates to a pharmaceutical composition comprising fenticonazole with an antibacterial agent, optionally one or more analgesics or local anesthetics agents and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • Inflammation of the vagina, or vaginitis is caused by various external and internal factors that alter the vaginal microbiota.
  • the most common causes of infectious vaginitis are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC) and trichomonal vaginitis (TV), representing about 90% of cases in women of reproductive age in first level clinics.
  • BV bacterial vaginosis
  • VVC vulvovaginal candidiasis
  • TV trichomonal vaginitis
  • a significant percentage of infectious vaginitis occurs in women of all ages, both sexually active and inactive, so many women have had a vaginal infection at least once in their life.
  • the healthy vaginal tract of reproductive-aged women is colonized by normal microbiota formed of lactobacilli, which protects against pathogenic bacterial species when present in sufficient numbers.
  • Vulvovaginal candidiasis is caused by the overgrowth of yeasts, mainly Candida albicans, which are essentially part of the vaginal flora. Symptoms of vulvovaginal candidiasis include vaginal discharge, itching, pain, and swelling. Although Candida albicans is the most common cause of vulvovaginal candidiasis, non albicans species of Candida, such as Candida glabrata. Candida parapsiiosis, Candida krusei, Candida cerevisiae, Candida tropicalis, Candida iusitaniae, and Trichosporon sp. have increasingly been identified as cause of vulvovaginal candidiasis. Bacterial and Candida infections can coexist. Mixed bacterial and Candida infection occurs in up to about one-fifth of vaginitis cases.
  • Trichomonas vaginalis is a flagellate protozoan parasite that causes trichomoniasis, characterized by profuse, yellow-green discharge and vaginal or vulvar irritation.
  • vaginal infection treatments include fungicidal and/or antibiotic treatment with azole derivatives.
  • Reference and consolidated therapies (either local or systemic) for the treatment of the above conditions are well stablished.
  • recommended regimens for bacterial vaginosis include:
  • Intravaginal clindamycin cream (2%) once daily for seven days or 300 mg orally twice daily for seven days, or
  • Recommended regimens for vaginal candidiasis include:
  • First line recommended regimens for the treatment of Trichomonas vaginalis include:
  • the increasing incidence of mixed vaginal infections poses a therapeutic challenge because such infections require treatment with multiple drugs.
  • European application EP 1712229 A1 discloses oral compositions containing fluconazole, tinidazole or secnidazole for treating vaginal infections of the type Gardnerella vaginalis, Actinomyces, Candida and Trichomonas vaginalis microorganisms present in vaginitis and bacterial vaginosis.
  • International application WO 2010026469 A1 discloses a pharmaceutical composition comprising the combination of fluconazole, tinidazole and clindamycin and/or pharmaceutically acceptable salts thereof for treating sexually transmitted infections.
  • Application EP 910377 A1 discloses pharmaceutical compositions for topical administration in the treatment of vaginitis comprising a combination of metronidazole and miconazole and one or more local anesthetics such as lidocaine or benzocaine.
  • WO 2005087270 A1 discloses a pharmaceutical composition for topical administration comprising terconazole and tinidazole and/or tioconazole
  • oral antifungal therapies favor that drug-resistant non-albicans species thrive and spread in the vagina, since a significant amount of drug remains in the gastrointestinal tract, reducing C. albicans and allowing less susceptible non-albicans species to grow.
  • such above therapies can be complicated by the emergence of drug-resistant yeasts with variable and even full resistance to conventional prescribed antifungal drugs such as fluconazole, tioconazole, clotrimazole and miconazole.
  • the present invention was made in view of the prior art described above, and the object of the present invention is, in a first aspect, to provide a new pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent or a pharmaceutically acceptable salt thereof, optionally one or more analgesics or local anesthetics agents, and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the pharmaceutical composition comprises a pharmaceutically effective amount of fenticonazole in combination with a pharmaceutically effective amount of an antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the pharmaceutical composition comprises a pharmaceutically effective amount of fenticonazole in combination with a pharmaceutically effective amount of an antibacterial agent, a pharmaceutically effective amount of an analgesic or a local anesthetic and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • fenticonazole is present as fenticonazole nitrate.
  • the antibacterial agent is tinidazole.
  • the analgesic or local anesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present invention is to provide a process for preparing a dosage form suitable for vaginal administration comprising the steps of mixing fenticonazole or a pharmaceutically salt thereof in combination with an antibacterial agent and, optionally an analgesic or local anesthetic and a pharmaceutically acceptable excipient and/or auxiliary agent, then, processing the mixture to produce the dosage form.
  • Another aspect of the invention is a pharmaceutical composition comprising the combination of the first aspect for use as a medicament for the treatment of infectious diseases or conditions in female reproductive system, such as vulvovaginal infections.
  • the word “comprise” encompasses the case of “consisting of”. Additional objects, advantages and features of the invention will become apparent to those skilled in the art upon examination of the description or may be learned by practice of the invention.
  • the following examples and drawings are provided by way of illustration, and they are not intended to be limiting of the present invention.
  • the present invention covers all possible combinations of particular and preferred embodiments described herein.
  • the present invention is related to an association or combination of fenticonazole and an antibacterial agent, and optionally with an analgesic or local anesthetic, for use in the treatment of infectious diseases conditions in female reproductive system.
  • Fenticonazole is an imidazole derivative exhibiting wide spectrum antimycotic activity. It also exerts antibacterial activity, with a spectrum that includes Gram-positive bacteria (Staphylococcus aureus, Staphylococcus epidermis, Streptococcus spp.) and antiparasitic action against Triconomonas vaginalis and some bacterial species such as Gardnerella vaginalis.
  • Fenticonazole is well absorbed through the vaginal wall and it is retained in the outermost layer of the epidermis (stratum corneum) for a long time. This allows its accumulation in the mucosal tissue up to 72 hours, thus maintaining its activity during a long period and delaying consecutive administration. Furthermore, fenticonazole is poorly absorbed at a systemic level.
  • the present invention provides, a pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • fenticonazole is present as fenticonazole nitrate.
  • fenticonazole or a pharmaceutically acceptable thereof can be included in the composition of the invention in an amount of about 0.5% to about 70%, for example about 5% to about 60%, or about 10% to about 55%, or about 15% to 50% by weight.
  • fenticonazole is present in the composition of the invention in an amount of about 20 to 50% by weight, more preferably of about 25% to 48% by weight.
  • the amount of fenticonazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 50 mg to about 2000 mg, more preferably from about 100 mg to about 1500 mg, and even more preferably from about 200 mg to about 1000 mg. In a more preferred embodiment, the amount of fenticonazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is 600 mg.
  • the antibacterial agent can comprise any antibacterial known in the art to be useful in treatment of bacterial infections of the vulvovaginal system.
  • antibacterials that can be useful include without limitation acriflavine, ampicillin, ceftriaxone, chloramphenicol, chlorquinaldol, ketoconazole, clindamycin, iodoquinol, metronidazole, nimorazole, ornidazole, pivampicillin, secnidazole, spiramycin, tetracycline, tinidazole, dequalinium chloride and pharmaceutically acceptable salts and esters thereof, combinations thereof and the like.
  • the antibacterial agent is selected from clindamycin, metronidazole, ketoconazole and tinidazole. In a most preferred embodiment, the antibacterial agent is tinidazole.
  • the antibacterial agent can be included in the composition of the invention in an amount of about 0.5% to about 70%, for example about 5% to about 60%, or about 10% to about 55%, or about 15% to 50% by weight.
  • fenticonazole is present in the composition of the invention in an amount of about 20 to 50% by weight, more preferably of about 25% to 48% by weight.
  • the amount of the antibacterial agent or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention will depend of the activity of the specific antibacterial agent employed and the type of dosage form of the vaginal composition used typically, the amount of antibacterial agent in the pharmaceutical compositions of the invention is preferably from about 10 mg to about 10000 mg, more preferably from about 100 mg to about 5000 mg, still more preferably from about 500 mg to about 3000 mg, and even still more preferably from about 1000 mg to about 2000 mg.
  • the antibacterial agent used in the pharmaceutical compositions of the invention is tinidazole or a pharmaceutically acceptable salt thereof.
  • the amount of tinidazole or a salt thereof in the pharmaceutical compositions of the invention is from about 200 mg to 5000 mg, more preferably from 500 mg to 3000 mg. In a more preferred embodiment, the amount of tinidazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 1000 mg to about 2000 mg.
  • the antibacterial agent used in the pharmaceutical compositions of the invention is metronidazole or a pharmaceutically acceptable salt thereof.
  • the amount of metronidazole or a salt thereof in the pharmaceutical compositions of the invention is from about 10 mg to 800 mg, more preferably from 200 mg to 600 mg.
  • the amount of metronidazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 300 mg to about 600 mg, preferably of about 500 mg.
  • the antibacterial agent used in the pharmaceutical compositions of the invention is ketoconazole or a pharmaceutically acceptable salt thereof.
  • the amount of ketoconazole or a salt thereof in the pharmaceutical compositions of the invention is from about 200 mg to 2000 mg, more preferably from 500 mg to 1000 mg. In a more preferred embodiment, the amount of ketoconazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 600 mg to about 900 mg, preferably of about 800 mg.
  • the antibacterial agent used in the pharmaceutical compositions of the invention is clindamycin or a pharmaceutically acceptable salt thereof. Typically, the amount of clindamycin or a salt thereof in the pharmaceutical compositions of the invention is from about 50 mg to 200 mg, more preferably from 750 mg to 150 mg. In a more preferred embodiment, the amount of clindamycin or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 90 mg to about 120 mg, preferably of about 100 mg.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising from 200 mg to about 1000 mg fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with 500 mg to 3000 mg tinidazole or a pharmaceutically acceptable salt thereof as antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a pharmaceutically acceptable salt thereof as antifungal agent in combination with 1000 mg to about 2000 mg tinidazole or a pharmaceutically acceptable salt thereof as antibacterial agent and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the relative amount of fenticonazole or a pharmaceutically acceptable salt thereof to antibacterial agent is in the range of from about 10:1 to about 1 :10 on a weight basis. In another embodiment, the relative amounts of fenticonazole or a pharmaceutically acceptable salt thereof to antibacterial agent in the range of from about 7:1 to about 1 :7, preferably from 4:1 to 1 :4. In a further aspect of the invention, the pharmaceutical composition according to the invention can further comprise one or more analgesics or local anesthetics agents.
  • analgesics include butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, levorphanol, meperidine, methadone, morphine, naloxone, oxycodone, oxymorphone, pentazocines propoxyphene, pharmaceutically acceptable salts and esters thereof, and combinations thereof.
  • Non-limiting examples of local anesthetics include benzocaine, bupivacaine, butamben, chloroprocaine, lidocaine, mepivacaine, pramoxine, prilocaine, procaine, proparacaine, ropivacaine, tetracaine, pharmaceutically acceptable salts and esters thereof, and combinations thereof.
  • the local anesthetic is lidocaine or a pharmaceutically acceptable salt thereof.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising fenticonazole or a salt thereof as antifungal agent, one from tinidazole, metronidazole, ketoconazole, clindamycin or salts thereof as antibacterial agent, lidocaine or a salt thereof as analgesic or local anesthetic agent, and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the analgesic or a local anesthetic can be included in a composition of the invention in an amount of about 0.1% to about 20%, for example about 0.5% to about 5%, or about 1% to about 3%, by weight.
  • the compositions of the invention can for example contain from about 0.1% to 3.5%, preferably about 2% by weight of lidocaine, and from about 0.1% to 3.0%, preferably about 1.5% by weight of lidocaine.
  • the amount of lidocaine or a salt thereof in the pharmaceutical compositions is from about 1 mg to 500 mg, more preferably from 10 mg to 400 mg. In a more preferred embodiment, the amount of lidocaine or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is from about 50 mg to about 200 mg, preferably about 100 mg lidocaine.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising from about 200 mg to about 1000 mg fenticonazole or a salt thereof as antifungal agent in combination with from about 500 mg to about 3000 mg tinidazole or a salt thereof as antibacterial agent and 50 mg to 200 mg lidocaine or a salt thereof as local anesthetic agent a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 1000 mg to about 2000 mg tinidazole or a salt thereof as antibacterial agent and 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 200 mg to about 2000 mg ketoconazole or a salt thereof as antibacterial agent and optionally, 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the present invention provides a pharmaceutical composition suitable for vaginal delivery comprising 600 mg fenticonazole or a salt thereof as antifungal agent in combination with 50 mg to about 150 mg clindamycin or a salt thereof as antibacterial agent and optionally, 75 mg to 150 mg lidocaine or a salt thereof and a pharmaceutically acceptable excipient and/or auxiliary agent.
  • the pharmaceutical composition suitable for vaginal delivery according to the present invention can be present in a dosage form which includes but it is not limited to tablets, hard or soft gelatin capsules, creams, suppositories, pessaries, foams, ointments, gels, films, tampons, vaginal rings and douches.
  • the compositions take the form of pessaries.
  • the pharmaceutical composition may be in the form of a pessary containing the pharmaceutical composition suitable for vaginal delivery of the invention and a pessary base.
  • the pessary base may be of any conventional material for vaginal administration such as glycerinated glycerin, macrogols (polyethylene glycols), natural, synthetic or semisynthetic hard fats, and fractionated palm kernel oil and mixtures thereof.
  • a particularly preferred material is a hard fat such as triglyceride esters.
  • the pessary base amounts from about 1% to about 90% by weight of the composition, for example from about 10% to about 70%, or from about 20% to about 60% by weight of the composition.
  • the pessary base can also comprise a surfactant to promote dispersal of the active substances and give continuous penetration of the active substances into the mucosa.
  • Suitable surfactant agents may be selected from the group consisting of but not limited to benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docusate sodium, glycine, hypromellose, phospholipids, polysorbates, poloxamer, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates, sodium lauryl sulfate, sorbitan esters, tricaprylin or mixtures thereof.
  • the surfactant is polysorbate.
  • the surfactant agent may be present in an amount from about 0% to 30% by weight, preferably from about 0% to about 20%, more preferably from 0% to 15% based on the total weight of the composition.
  • the pessary may include at least one or more further auxiliary agents, to afford the appropriate mechanical and release properties. All such auxiliary agents must be compatible with the other ingredients of the dosage form and not injurious to the human being .
  • the auxiliary agent may be selected from the group consisting of diluents, solubilizing agents, emulsifying agents and antioxidants, and/or mixtures thereof.
  • Suitable solubilizing agents include corn oil (maize), polyethylene glycol, glycerin, cottonseed oil, dibutyl phthalate, diethyl phthalate, dimethyl ether, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, ethyl acetate, ethyl alcohol, ethyl lactate, ethyl oleate, glycofurol, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium-chain triglycerides, methyl lactate, mineral oil, monoethanolamine, octyldodecanol, olive oil, peanut oil, polyoxyl 35 castor oil, propylene carbonate, propylene glycol, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprylin, triethanolamine, triethyl citrate, triolein, water,
  • the solubilizing agent may be present in an amount from about 0% to 80% by weight, preferably from about 0% to about 50%, more preferably from 0% to 30% based on the total weight of the composition.
  • Emulsifying agents include lecithin, yucca extract, quillaja bark extract, lanolin, candelilla, carnauba, jojoba, rice bran, beeswax, xanthan gum, quince seed, glyceryl oleate, glyceryl stearate, citrate and mixtures thereof.
  • the emulsifying agent may be present in an amount from about 0.05% to 20% by weight, preferably from about 0.1% to about 15%, more preferably from 0.2% to 10% based on the total weight of the composition.
  • the emulsifying agent may also be used as solubilizing agent.
  • Suitable antioxidant agents include Pythrox LT 10-IP (lecithin, ascorbyl palmitate + tocopherol rch extract, sunflower oil), vitamin E (tocopheryl asetate/tocopheroll), ascorbic acid (vitamin C) or ascorbyl palmitat propolis extract, allium cepae (onion) bulb extract, glycyrrhiza glabra (organic licorice) root extract, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), sodium metabisulfite, propyl gallateand cysteine and mixtures thereof.
  • Particularly preferred antioxidants according to the present invention are butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) or mixtures thereof.
  • the antioxidant agent may be present in an amount from about 0.005% to 5% by weight, preferably from about 0.01% to about 4%, more preferably from 0.1% to 3% based on the total weight of the composition.
  • composition suitable for vaginal delivery of the present invention can be used for other pharmaceutical preparations or dosage forms, for example for tablets, hard or soft gelatin capsules, creams, foams, ointments, gels, films, tampons, vaginal rings and douches.
  • the pharmaceutical composition suitable for vaginal delivery of the present invention may be in the form of a cream.
  • a conventional cream base may be used, e.g. containing oily or waxy materials such as liquid paraffin, white petroleum or cetyl alcohol, water and one or more surfactants to produce a water- in-oil emulsion.
  • the pharmaceutical composition suitable for vaginal delivery of the invention may be in the form of vaginal tablets.
  • the tablet comprises a combination of fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent, optionally together with one or more an analgesics or local anesthetics, and at least one pharmaceutically acceptable excipient or carrier, characterized in that the tablet comprises granules comprising the fenticonazole or a pharmaceutically acceptable salt thereof and/or the antibacterial agent and a pharmaceutically acceptable excipient and optionally, extragranular excipients.
  • the intragranular and extragranular excipients can comprise one or more of binder, diluent, lubricant and disintegrant agents.
  • Suitable diluents include corn starch, microcrystalline cellulose, powdered cellulose, silicified cellulose, lactose monohydrate, anhydrous lactose, mannitol, sorbitol, sucrose, fructose, dextrose, and/or mixtures thereof.
  • lactose monohydrate and microcrystalline cellulose are used.
  • Diluents may be presents in an amount from about 20% to about 95% by weight, preferably from 35% to 90% by weight, and more preferably from 30 to 85% by weight of the total weight of the composition.
  • the dosage form according to the invention comprises a binder.
  • the binding agent can be selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, and/or mixtures thereof.
  • Binders may be presents in an amount from about 0.5% to about 20% by weight, preferably from 1 % to 18% by weight, and more preferably from 5 to 15% by weight of the total weight of the composition.
  • the dosage form according to the invention can also comprise a disintegration agent.
  • Disintegrating agents may be selected from the group consisting of low- substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, crospovidone, sodium croscarmellose, and/or mixtures thereof. Preferably sodium croscarmellose is used.
  • Disintegrating agents may be present in an amount from about 2% to about 50% by weight, preferably from about 5% to about 45% by weight, and more preferably from 10% to 40% by weight of the total weight of the composition.
  • Lubricants and antiadherent agents are excipients that reduce interparticular friction and prevent adhesion of drug particles and improve fluidity of granular or pulverulent compositions.
  • Lubricants may be selected from the group consisting of talc, alkaline earth salts of stearic acid, specially magnesium and calcium stearate, stearic acid, glycerin palmitostearate, stearyl fumarate, and/or mixtures thereof.
  • the lubricant may be present in an amount from about 0% to 5% by weight, preferably from about 0% to about 3% based on the total weight of the composition.
  • the antiadherent agent may be present in an amount from about 0% to 5% by weight, preferably from about 0% to about 3% based on the total weight of the composition.
  • the pharmaceutical composition suitable for vaginal delivery of the invention may be in the form of vaginal capsules.
  • the vaginal capsule comprises a combination of fenticonazole or a pharmaceutically acceptable salt thereof with an antibacterial agent, optionally together with one or more an analgesics or local anesthetics, and at least one pharmaceutically acceptable excipient or carrier as defined above.
  • the excipients can comprise one or more of disintegrant, filler/diluent, binder/adhesive, glidant and lubricant agents using the amounts or percentages stated above.
  • Suitable disintegrants may comprise but not limited to sodium starch glycolate, crosscarmellose sodium, crospovidone, aligns, gums, surfactants and the like and mixtures thereof.
  • Suitable fillers/diluents may comprise but not limited to dibasic calcium phosphate dihydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
  • Suitable binders/adhesives may comprise but not limited to polyvinylpyrrolidone (povidone), gelatin, sugars, glucose, natural gums, synthetic celluloses, polymethycrylate, cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose and the like and mixtures thereof.
  • polyvinylpyrrolidone povidone
  • gelatin sugars
  • glucose natural gums
  • synthetic celluloses polymethycrylate
  • cellulose derivatives such as hydroxypropyl methyl cellulose, hydroxypropyl cellulose, carboxy methyl cellulose, methyl cellulose and the like and mixtures thereof.
  • Suitable glidants may comprise but not limited to colloidal silicon dioxide, talc, aluminium silicate and the like and mixtures thereof.
  • Suitable lubricants may comprise but not limited to magnesium stearate, sodium stearyl fumarate, polyethylene glycol, stearic acid, metal stearates, talc, boric acid, sodium chloride benzoate and acetate, sodium or magnesium lauryl sulfate and the like and mixtures thereof.
  • Another aspect of the present invention is, therefore, a process for preparing a dosage form suitable for vaginal administration comprising fenticonazole or a pharmaceutically salt thereof in combination an antibacterial agent, a pharmaceutically acceptable excipient and/or auxiliary agent and optionally, an analgesic or a local anesthetic.
  • the process comprises the steps of mixing fenticonazole or a pharmaceutically salt thereof, an antibacterial agent and optionally, an analgesic or a local anesthetic agent with at least one pharmaceutically acceptable excipient and/or auxiliary agent and, then, processing the mixture to produce the dosage form.
  • the mixture is processed by filling it into capsules or compressing it to obtain tablets.
  • the composition is suitable for administration in a single dose on a single day.
  • a preferred embodiment of the invention provides a process for the production of a pessary comprising fenticonazole or a pharmaceutically salt thereof in combination an antibacterial agent, a pharmaceutically acceptable excipient and/or auxiliary agent, and optionally an analgesic or a local anesthetic, comprising the following steps: a) Hard fat is melted b) If present, the surfactant and/or the solubilizing agent is added to the melted fat c) Fenticonazole, the antibacterial agent and optionally the analgesic or a local anesthetic are added to the melted hard fat of step a) or to the mixture obtained in step b) until homogeneous product is obtained d) the final product is filled in an appropriate package
  • Another aspect of the invention is the pharmaceutical composition suitable for vaginal delivery comprising: a) fenticonazole or a pharmaceutically acceptable salt thereof and b) an antibacterial agent
  • the invention is directed to the pharmaceutical composition suitable for vaginal delivery for use in the treatment of infectious diseases or conditions in female reproductive system, such as vulvovaginal infections
  • Vulvovaginal infections include bacterial vaginosis, vulvovaginal candidiasis (both albicans and non-albicans caused infections), trichomonal vaginitis and mixed infections.
  • the antibacterial agent is selected from acriflavine, ampicillin, ceftriaxone, chloramphenicol, chlorquinaldol, ketoconazole, clindamycin, iodoquinol, metronidazole, nimorazole, ornidazole, pivampicillin, secnidazole, spiramycin, tetracycline, tinidazole, dequalinium chloride and pharmaceutically acceptable salts and esters thereof and combinations thereof.
  • clindamycin, metronidazole, ketoconazole and tinidazole is tinidazole.
  • composition of the invention is also considered to be effective in treating any secondary candidial, bacterial and/or trichomonal infections which might result from treatment of such causative agents.
  • Vaginal infections due to group B and D streptococcus and the like, infections due to microorganisms causing vulvitis and vulvovaginitis, and other vaginal infections e. g. atrophic vaginitis, allergic or irritant vulvo vaginitis, genital psoriasis (with or without clinically relevant infection), vulvitis due to Lichen sclerosis, etc.
  • vaginal infections due to group B and D streptococcus and the like
  • infections due to microorganisms causing vulvitis and vulvovaginitis e. g. atrophic vaginitis, allergic or irritant vulvo vaginitis, genital psoriasis (with or without clinically relevant infection), vulvitis
  • compositions in accordance with the invention may also find more general use in treating primary and/or secondary genital infections in both men and women, including sexually transmitted infections, e. g. infections due to chlamydia; balanitis; penile dermatitis; herpes genitalis; gonorrhea; etc.
  • Another aspect of the invention is directed to the pharmaceutical composition suitable for vaginal delivery for use in the treatment of any secondary Candida, bacterial and/or trichomonas infections which might result from treatment of such causative agents, and in general, in the treatment primary and/or secondary genital infections in both men and women, such us infections due to chlamydia; balanitis; penile dermatitis; herpes genitalis; gonorrhea; etc.
  • the antibacterial agent is selected from clindamycin, metronidazole, ketoconazole and tinidazole. In a most preferred embodiment, the antibacterial agent is tinidazole.
  • the following antifungal agents could be used in the formulation of the invention: econazole, sertaconazol, or their pharmaceutically acceptable salts or mixtures thereof.
  • the amount of econazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 10 mg to about 500 mg, more preferably from about 20 mg to about 400 mg, and even more preferably from about 50 mg to about 300 mg. In a more preferred embodiment, the amount of econazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is 150 mg.
  • the amount of sertaconazole or a pharmaceutically acceptable salt thereof in the pharmaceutical composition of the invention is preferably from about 80 mg to 600 mg more preferably from 150 mg to 400 mg and more preferably from 200 mg to 350 mg.
  • the pharmaceutical composition according to the present invention may be presented in a pack to providea complete course of treatment.
  • Packs comprising at least one formulation containing the pharmaceutical composition according to the present invention are considered to form part of the invention.
  • Example 1 A pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the following composition:
  • Unit Formula may contain one of Tinidazole, Metronidazole, Ketoconazole or Clindamycin.
  • Lidocaine ( w/wo ) means “Unit Formula with or without the presence of Lidocaine”.
  • the amount of lidocaine is substituted by hard fat in the above formula General manufacturing process:
  • surfactant and/or solubilizing agent(s) and/or is added and mixed (depends on the unit formula)
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 3
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
  • Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 4
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 5
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 6
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 7
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 8
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
  • Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 9
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin Example 10
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of pessary is prepared according to the general process disclosed in example 1 , with the following composition:
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of vaginal tablet is prepared according to the following composition:
  • PVP polysorbate and ascorbic acid is solved in a proper solvent or solvent mixture as granulation solution.
  • APIs, MCC and crospovidone are mixed to obtain homogeneous powder and granulate with granulation solution. 3. These granules are sieved and dried.
  • a pharmaceutical composition including a fenticonazole or a salt thereof combination according to the invention in the form of vaginal capsule is prepared according to the following composition: Unit Formula contains only one of Tinidazoie, Metronidazole, Ketoconazole or Clindamycin
  • APIs, lactose and croscarmellose sodium, sodium starch glycolate, HPC, and, tartaric acid are sived and mixed to obtain homogenious powder.
  • Colloidal silicone dioxide are added by sieving and mixed.
  • magnesium stearate is added by sieving and mixed for a short time.
  • Stability studies were performed in the pharmaceutical composition according to the present invention. Particularly, stability studies were performed by using the pharmaceutical composition of the present invention with and without Lidocaine.
  • PIPLC analytical test methods for fenticonazole nitrate, tinidazoie and lidocaine (w/wo) ovule product are detailed below.
  • a detailed information for Impurities A to D of Fenticonazole Nitrate can be found at the European Pharmacopeia 10.0, 07/2014:1211 , corrected 10.0, p. 2622-2624, which is incorporated herein by reference.
  • a detailed information for Impurities A and B of Tinidazole can be found at the European Pharmacopeia 10.0, 01/2017:1051 , p. 4048-4049, which is incorporated herein by reference.
  • STABILITY ASSAYS for Example 2 without lidocaine Stability of formulation according to example 2 without lidocaine (the amount of lidocaine is substituted by the same amount of hard fat) comprising fenticonazole nitrate and tinidazole as active ingredients was tested at different conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation d'une combinaison comprenant du fenticonazole et un agent antibactérien dans un procédé thérapeutique chez des femmes ayant des affections du système vulvo-vaginal dans lesquelles une telle combinaison d'agents actifs est indiquée. L'invention concerne des compositions pharmaceutiques appropriées pour l'administration vaginale d'une combinaison de fenticonazole avec un agent antibactérien, éventuellement d'un ou de plusieurs analgésiques ou anesthésiques locaux et d'excipients ou de supports pharmaceutiquement acceptables.
PCT/TR2021/050086 2020-01-31 2021-01-29 Composition pharmaceutique appropriée pour une administration vaginale Ceased WO2021154188A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
BR112022015112A BR112022015112A2 (pt) 2020-01-31 2021-01-29 Composição farmacêutica adequada para liberação vaginal e uso da mesma
MX2022009303A MX2022009303A (es) 2020-01-31 2021-01-29 Composicion farmaceutica adecuada para la administracion vaginal.
EP21748063.1A EP4096655A4 (fr) 2020-01-31 2021-01-29 Composition pharmaceutique appropriée pour une administration vaginale

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2020/01511 2020-01-31
TR202001511 2020-01-31

Publications (1)

Publication Number Publication Date
WO2021154188A1 true WO2021154188A1 (fr) 2021-08-05

Family

ID=77079220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2021/050086 Ceased WO2021154188A1 (fr) 2020-01-31 2021-01-29 Composition pharmaceutique appropriée pour une administration vaginale

Country Status (5)

Country Link
EP (1) EP4096655A4 (fr)
BR (1) BR112022015112A2 (fr)
EC (1) ECSP22067445A (fr)
MX (1) MX2022009303A (fr)
WO (1) WO2021154188A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087270A1 (fr) * 2004-03-10 2005-09-22 Edko Trading And Representation Co. Ltd. Compositions anti-vaginite comprenant un triazole
WO2006060462A1 (fr) * 2004-12-01 2006-06-08 Johnson & Johnson Consumer Companies, Inc. Préparations et méthodes de traitement d'irritations et kit correspondant
RU2016138895A (ru) * 2016-10-03 2018-04-04 Михаил Лукич Ткаченко Антигрибковая композиция эвтектического типа (варианты)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103690476A (zh) * 2014-01-06 2014-04-02 海南海力制药有限公司 微粉化硝酸芬替康唑制剂组合物及其制备方法
TR201413590A3 (en) * 2014-11-17 2021-06-21 Pharmaceutical composition for use in treatment of vaginal infection comprises active substance or its derivative exhibiting antiprotozoal activity, and local anesthetic agent
EP3244890B1 (fr) * 2014-12-20 2025-05-21 Gregg, John Malcolm Hall Ornidazole pour son utilisation dans le traitement des infections causées par burkholderia mallei ou burkholderia pseudomallei
CN108079098A (zh) * 2018-02-28 2018-05-29 翔宇药业股份有限公司 抗真菌感染的药物制剂及其制作方法
CN108210448A (zh) * 2018-04-09 2018-06-29 翔宇药业股份有限公司 硝酸芬替康唑栓剂及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087270A1 (fr) * 2004-03-10 2005-09-22 Edko Trading And Representation Co. Ltd. Compositions anti-vaginite comprenant un triazole
WO2006060462A1 (fr) * 2004-12-01 2006-06-08 Johnson & Johnson Consumer Companies, Inc. Préparations et méthodes de traitement d'irritations et kit correspondant
RU2016138895A (ru) * 2016-10-03 2018-04-04 Михаил Лукич Ткаченко Антигрибковая композиция эвтектического типа (варианты)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4096655A4 *

Also Published As

Publication number Publication date
ECSP22067445A (es) 2022-11-30
EP4096655A1 (fr) 2022-12-07
EP4096655A4 (fr) 2024-02-28
MX2022009303A (es) 2022-09-19
BR112022015112A2 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
CN102946869B (zh) γ-羟基丁酸的速释制剂及剂型
JP6259490B2 (ja) ベンダムスチンの経口投与形及びその治療的使用
CA2182004C (fr) Comprimes enrobes de paracetamol et de domperidone
AU2011219452B2 (en) Veterinary compositions
US20060140990A1 (en) Composition for topical treatment of mixed vaginal infections
CA2766884C (fr) Compositions a dose pharmaceutique solide fixe comprenant de l'irbesartan et de l'amlodipine, leur preparation et leur application therapeutique
MX2007001706A (es) Formulacion de comprimidos de liberacion extendida que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para su fabricacion y su uso.
JP6276756B2 (ja) １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
CN1960763A (zh) 抗阴道炎组合物
TW202143997A (zh) 口服藥物組合物
JP2001513550A (ja) 新規医薬組成物
RU2828262C1 (ru) Фармацевтическая композиция, подходящая для внутривлагалищной доставки
EP4096655A1 (fr) Composition pharmaceutique appropriée pour une administration vaginale
KR101653424B1 (ko) 성전염성 감염 치료에 사용하기 위한 약학적 조성물
US20060002997A1 (en) Nitrofurantoin controlled release dosage form
US20070154516A1 (en) Drug delivery system
WO2021011622A1 (fr) Capsule de gélatine molle de secnidazole et procédés et utilisations de celle-ci
RU2707286C1 (ru) Фармацевтическая противогрибковая композиция на основе производного хлорфенилбутандиона и способ её получения
CN1771989A (zh) 一种治疗妇科炎症的复方制剂
HK1204552B (en) Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
AU2014208223A1 (en) Veterinary compositions
HK1103650A (en) Anti-vaginitis compositions comprising a triazole
HK1169309B (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2014051532A1 (fr) Formulations en comprimé pharmaceutique comprenant du cefdinir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21748063

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112022015112

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021748063

Country of ref document: EP

Effective date: 20220831

ENP Entry into the national phase

Ref document number: 112022015112

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20220729